

Revised

PROGRAM

April 18 (Sun), 2010

16:30-18:00 Registration

19:00-21:00 *Welcome Reception*

Magnolia, B1F

April 19 (Mon), 2010

08:15-08:30 **Opening Remarks**

Daigo, B2F

Session 1 VIRUS STRUCTURE, BIOLOGY 1 chair: P.Bates, Y. Kawaoka

Daigo, B2F

08:30-09:00 1S-1 **Stephan Becker**
Philipps-Universität Marburg, Germany

MARBURG VIRUS BUDDING

09:00-09:30 1S-2 **Elke Muehlberger**
Boston University, USA

INTERACTION OF FILOVIRUSES WITH THE HOST'S DEFENSE MACHINERY

09:30-09:45 1S-3 **Asuka Nanbo**
University of Wisconsin-Madison, USA

EBOLAVIRUS IS INTERNALIZED INTO HOST CELLS VIA MACROPINOCYTOSIS IN A VIRAL GLYCOPROTEIN-DEPENDENT MANNER

09:45-10:00 1S-4 **M. F. Saeed**
University of Texas Medical Branch, USA

EBOLA VIRUS USES MACROPINOCYTOSIS AND IS TRAFFICKED TO THE GOLGI COMPLEX BEFORE NUCLEOCAPSID RELEASE INTO THE CELL CYTOPLASM

10:00-10:15 *Coffee Break*

Saga, B2F

10:15-10:45 1S-5 **Erica O Saphire**
The Scripps Research Institute, USA

CRYSTAL STRUCTURE OF SUDAN GP REVEALS A SHARED SOLUTION FOR NEUTRALIZING EBOLAVIRUSES

10:45-11:00 1S-6 **Chris R. Kimberlin**
TSRI, USA

EBOLAVIRUS VP35 USES A BIMODAL STRATEGY TO BIND DSRNA FOR INNATE IMMUNE SUPPRESSION

11:00-11:15 1S-7 **Masfique Mehedi**
Public Health Agency of Canada, Canada

IDENTIFICATION OF A NEW EBOLA VIRUS SOLUBLE GLYCOPROTEIN (ssGP)

11:15-11:30 1S-8 **Keita Matsuno**
Hokkaido University, Japan

DIFFERENT POTENTIAL OF C-TYPE LECTIN-MEDIATED ENTRY BETWEEN MARBURG VIRUS STRAINS

11:30-13:45 *Lunch Break & POSTER SESSION*

Saga, B2F

Session 2 PATHOLOGY & PATHOGENESIS chair: T. Geisbert, S. Zaki

Daigo, B2F

13:45-14:15 2S-1 **Lisa E. Hensley**
US Army Medical Research Institute for Infectious Diseases, USA

EVALUATION OF AN ANTIBODY TARGETING A HOST PROTEIN FOR TREATMENT OF EBOLA AND PREDICTORS OF SURVIVAL

14:15-14:45 2S-2 **Christopher F. Basler**
Mount Sinai School of Medicine, USA

THE STRUCTURAL BASIS FOR VP35 INTERFERON-ANTAGONIST AND POLYMERASE CO-FACTOR FUNCTIONS

14:45-15:00 2S-3 **Anna N. Honko**
US Army Medical Research Institute for Infectious Diseases, USA

DEVELOPMENT OF ANIMAL MODELS FOR COTE D'IVOIRE AND BUNDIRUGYO EBOLA VIRUS: COMPARISON WITH EXISTING MODELS

15:00-15:15 *Coffee Break*

Saga, B2F

15:15-15:45 2S-4 **Judith M White**
University of Virginia, USA

CONTROL OF EBOLAVIRUS ENTRY AND TROPISM BY CELL ADHESION-DEPENDENT RECEPTOR TRANSLOCATION: POTENTIAL RELEVANCE OF A POOL OF RECEPTOR FOUND IN LYMPHOCYTES.

15:45-16:15 2S-5 **Michael G. Katze**
University of Washington, USA

HOW CAN WE SAVE THE WORLD FROM THE NEXT PANDEMIC-CAN SYSTEMS AND COMPUTATIONAL BIOLOGY BE MORE EFFECTIVE THAN 50 YEARS OF TRADITIONAL VIROLOGY?

16:15-16:30 2S-6 **Anthony C. Wong**
Albert Einstein College of Medicine, USA

A FORWARD GENETIC STRATEGY REVEALS DESTABILIZING MUTATIONS IN THE EBOLAVIRUS GLYCOPROTEIN THAT ALTER ITS PROTEASE DEPENDENCE DURING CELL ENTRY

16:30-16:45 *Coffee Break*

Saga, B2F

16:45-17:15 2S-7 **Hideki Ebihara**
National Institute of Allergy and Infectious Diseases, USA

PATHOGENESIS OF FILOVIRUSES IN SMALL ANIMAL MODELS

17:15-17:45 2S-8 **Viktor Volchkov**
Claude Bernard University Lyon, France

TBA

18:30~ *Houseboat Cruise (Yakata Bune)*

Outside Hotel

April 20 (Tue), 2010

Session 3		PROPHYLAXIS & THERAPY 1	chair: K. Johnson	Daigo, B2F
08:30-08:45	P-21	Chinglai Yang Emory University School of Medicine, USA	IMMUNIZATION BY A MIXTURE OF DNA AND VLP VACCINES INDUCES BOTH ANTIBODY AND T CELL RESPONSES AND CONFERS MORE EFFECTIVE PROTECTION AGAINST LETHAL EBOV CHALLENGE	
08:45-09:00	P-19	Ronald N. Harty University of Pennsylvania, USA	HOST INNATE IMMUNE INTERACTIONS WITH EBOLA VIRUS GP, VP40, AND VIRUS-LIKE PARTICLES (VLPs).	
09:00-09:30	3S-2	Nancy J. Sullivan National Institutes of Health, USA	COMPARATIVE IMMUNOGENICITY AND EFFICACY OF REPLICATION-DEFECTIVE ADENOVIRUS VECTORS FOR VACCINE PROTECTION AGAINST FILOVIRUSES	
09:30-10:00	3S-3	Kelly L Warfield Integrated Biotherapeutics, USA	ADVANCED DEVELOPMENT OF A PAN-FILOVIRUS-LIKE PARTICLE VACCINE	
10:00-10:15	<i>Coffee Break</i>			Saga, B2F
10:15-10:30	3S-4	John M. Dye US Army Medical Research Institute for Infectious Diseases, USA	POST-EXPOSURE TRANSFER OF IMMUNOGLOBULIN G FROM CONVALESCENT SURVIVORS PROTECTS RHESUS MACAQUES FROM MARBURG VIRUS	
10:30-11:00	3S-5	Andrea Marzi National Institute of Allergy and Infectious Diseases, USA	DEVELOPMENT OF A SINGLE CROSS-PROTECTIVE EBOLA VIRUS VACCINE	
	3S-6	Heinz Feldmann National Institute of Allergy and Infectious Diseases, USA	REPLICATION-COMPETENT VACCINES FOR FILOVIRUSES	
11:00-11:30	3S-7	Peter Halfmann University of Wisconsin, USA Yoshihiro Kawaoka The University of Tokyo, Japan	PROTECTIVE EFFICACY OF A REPLICATION-INCOMPETENT EBOLAVIRUS	
11:30-13:00	<i>Lunch Break</i>			Saga, B2F
Session 4		PROPHYLAXIS & THERAPY 2	chair: L. Hensley	Daigo, B2F
13:00-13:30	4S-1	Gene G Olinger US Army Medical Research Institute for Infectious Diseases, USA	POTENTIAL EBOLA THERAPIES IDENTIFIED USING HIGH THROUGHPUT PHENOTYPIC SCREENING OF DRUGS AND COMBINATIONS	
13:30-14:00	4S-2	Ian MacLachlan Tekmira Pharmaceuticals Corporation, Canada Thomas Geisbert Boston University, USA	POSTEXPOSURE PROTECTION OF NONHUMAN PRIMATES AGAINST A LETHAL EBOLA VIRUS CHALLENGE BY RNA INTERFERENCE	
14:00-14:15	4S-3	Jason S. Richardson Public Health Agency of Canada, Canada	IMPACT OF SYSTEMIC OR MUCOSAL IMMUNITY TO ADENOVIRUS ON AD-BASED EBOLAVIRUS VACCINE IN GUINEA PIGS	
14:15-14:30	4S-4	Ling Ye Emory University, USA	IMMUNOGENICITY OF INSECT CELL-DERIVED EBOLA VLPs IN GUINEA PIGS VIA DIFFERENT DELIVERY ROUTES AND PROTECTION AGAINST LETHAL EBOV CHALLENGE	
14:30-14:45	<i>Coffee Break</i>			Saga, B2F
Session 5		CASE MANAGEMENT & DIAGNOSIS	chair: P.Formenty, D. Bausch	Daigo, B2F
14:45-15:00	5S-1	Daniel Bausch Tulane University, USA	EFFECTS OF VARIOUS METHODS OF VIRUS INACTIVATION ON CLINICAL LABORATORY PARAMETERS MEASURED IN HUMAN BLOOD: GUIDELINES FOR MANAGEMENT OF THE VIRAL HEMORRHAGIC FEVERS	
15:00-15:30	5S-2	Paul Roddy Médecins Sans Frontières, Spain	SUPPORTIVE CASE MANAGEMENT FOR FILOVIRUS HAEMORRHAGIC FEVER: THE ONGOING INITIATIVE FOR IMPROVING CLINICAL OUTCOME	
15:30-15:45	5S-3	Mark G. Kortepeter US Army Medical Research Institute for Infectious Diseases, USA	PATHOPHYSIOLOGIC ASSESSMENT OF EBOLA VIRUS INFECTION WITH AND WITHOUT INTRAVENOUS FLUID TREATMENT IN A NONHUMAN PRIMATE MODEL USING A MULTI-SENSOR TELEMETRY SYSTEM	
15:45-16:15	5S-4	George F. Risi Infectious Disease Specialists, USA	PREPARING A COMMUNITY HOSPITAL TO CARE FOR WORK RELATED EXPOSURES TO FILOVIRUSES	
16:15-16:30	<i>Coffee Break</i>			Saga, B2F
16:30-17:00	5S-5	Allen Grolla Public Health Agency of Canada, Canada	DEVELOPING A GENEXPERT BASED DETECTION SYSTEM FOR FILOVIRUSES	
17:00-17:30	5S-6	Stephan Günther University of Hamburg, Germany	MANAGEMENT OF NEEDLE STICK INJURY IN BSL4 LABORATORY, HAMBURG, GERMANY	
18:45~	Gala Dinner at Happon			Outside Hotel

April 21 (Wed), 2010

Session 6		VIRUS STRUCTURE, BIOLOGY 2	chair: J. White, S. Becker	Daigo, B2F
8:30-9:00	6S-1	Paul Bates University of Pennsylvania School of Medicine, USA	INTERACTION OF EBOLA GP WITH THE CELLULAR ANTIVIRAL FACTOR TETHERIN	
9:00-9:15	6S-2	Jens H. Kuhn Integrated Research Facility at Fort Detrick, NIH/NIAID/DCR, USA	EBOLAVIRUS DELTA-PEPTIDES MODULATE FILOVIRUS CELL ENTRY	
9:15-9:30	6S-3	Stefan Pöhlmann Hannover Medical School, Germany	FILOVIRUS GLYCOPROTEINS AND HIV VPU DIFFERENTIALLY COUNTERACT THE CELLULAR ANTIVIRAL PROTEIN TETHERIN	
Session 7		VIRUS ECOLOGY & EPIDEMIOLOGY	chair: G. van der Groen, S. Nichol	Daigo, B2F
09:30-10:00	7S-1	Patricia Reed Wildlife Conservation Society, USA	REMOTE MONITORING AS A TOOL FOR TRANSMISSION STUDIES OF EBOLAVIRUS AND OTHER EMERGING INFECTIOUS DISEASES	
10:00-10:30	7S-2	Peter D. Walsh Max Plank Institute for Evolutionary Anthropology, Germany	WILD SPECULATION ON THE WILDLIFE DYNAMICS OF FILOVIRUSES	
10:30-10:45		<i>Coffee Break</i>		Saga, B2F
10:45-11:15	7S-3	Nadia Wauquier Centre International de Recherches Medicales de Franceville, Gabon	HIGH PREVALENCE OF BOTH HUMORAL AND CELLULAR IMMUNITY TO ZAIRE EBOLAVIRUS AMONG RURAL POPULATIONS IN GABON	
11:15-11:45	7S-4	Jonathan S. Towner Centers for Disease Control and Prevention, USA	INVESTIGATIONS OF MARBURG VIRUS CIRCULATION AMONG EGYPTIAN FRUIT BATS IN SOUTHWEST UGANDA	
11:45-13:15		<i>Lunch Break</i>		Saga, B2F
Session 8		RESTON EBOLAVIRUS	chair: H. Feldmann	Daigo, B2F
13:15-13:45	8S-1	C.J. Peters Univeristy of Texas Medical Branch, USA	<i>TBA</i>	
13:45-14:15	8S-2	Mary Elizabeth Miranda Veterinary Public Health Consultant, Philippines	REVIEW OF RESTON EBOLAVIRUS STUDIES IN HUMAN AND ANIMALS IN THE PHILIPPINES	
14:15-14:45	8S-3	Pierre Formenty World Health Organization, Switzerland	<i>RESTON EBOLAVIRUS</i> EMERGENCE IN PIGS IN PHILIPPINES A NOVEL PATHOGEN FOR HUMANS?	
14:45-15:00		<i>Coffee Break</i>		Saga, B2F
15:00-15:30	8S-4	Stuart T. Nichol Centers for Disease Control and Prevention, USA	RESTON EBOLAVIRUS ACTIVITY IN PIGS IN THE PHILIPPINES	
15:30-16:00	8S-5	Sherif R. Zaki Centers for Disease Control and Prevention, USA	PATHOLOGIC FEATURES OF FILOVIRUS INFECTIONS	
16:00-16:15	8S-6	Glenn A. Marsh Australian Animal Health Laboratory, CSIRO, Australia	INFECTION OF PIGS WITH THE PHILIPPINES 2007 SWINE ISOLATE OF EBOLA RESTON VIRUS	
16:15-16:45	8S-7	Gary P. Kobinger Public Health Agency of Canada, Canada	PATHOGENICITY OF ZAIRE EBOLAVIRUS IN PIGS	
16:45-17:00		Concluding Remarks		Daigo, B2F
19:00~		<i>Dinner</i>		Saga, B2F